Clinical trials: Recurrent Adult Non-Hodgkin Lymphoma
Lymphoma
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Interleukin-12 may stimulate a person's white blood cells to kill lymphoma cells. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them…
- Trial name
- NCT00004260
- Testing
- recombinant interleukin-12, rituximab
- Where
- United States
- Sponsor
- Mayo Clinic
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
RATIONALE: Sorafenib and everolimus may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00474929
- Testing
- RAD001, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- Mayo Clinic
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Lymphoma
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or…
- Trial name
- NCT00003245
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lung Cancer
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells.
- Conditions
- Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006019
- Testing
- azacitidine, sodium phenylbutyrate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00021372
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 25 people
- Sponsor
- Fox Chase Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00536601
- Testing
- etoposide, cyclophosphamide, carmustine
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003395
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058292
- Testing
- filgrastim, rituximab, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of bevacizumab in treating patients who have non-Hodgkin's lymphoma. Monoclonal antibodies such as bevacizumab may stop the growth of cancer by stopping blood flow to the tumor.
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00016094
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Lymphoma
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00987493
- Testing
- rituximab, bendamustine hydrochloride, lenalidomide
- Where
- 16 sites in Switzerland
- Volunteers
- 49 people
- Sponsor
- Swiss Cancer Institute
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
This phase II trial studies how well giving lenalidomide with or without rituximab works in treating patients with progressive or relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01419795
- Testing
- lenalidomide, rituximab, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft Versus Host Disease, Leukemia
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00577278
- Testing
- rituximab, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent)…
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02304458
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia, Lymphoma
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating patients with refractory B-cell…
- Trial name
- NCT00126646
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- MedImmune LLC
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004105
- Testing
- estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
- Where
- United States
- Sponsor
- NYU Langone Health
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota